Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776832 | 1.00 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6353286 | 0.89 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6353284 | 0.89 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL14431174 | 0.88 | PPARD (0.57) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL5482062 | 0.88 | PPARD (0.57) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6348336 | 0.85 | HSD11B1 (0.53) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6348338 | 0.85 | HSD11B1 (0.53) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL5475523 | 0.84 | HTT (0.51) | PTGDR | |
| SCHEMBL6359905 | 0.83 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL6359906 | 0.83 | HSD11B1 (0.56) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | HSD11B1 668/4885CHRM2 2467/4885CHRM1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.